Amplitude Surgical – First Quarter 2019-20

Sales Growth of 6.0% at Constant Exchange Rates

Regulatory News:

Amplitude Surgical (Paris:AMPLI) (ISIN: FR0012789667, Ticker: AMPLI, eligible for PEA-PME plans) (“Amplitude” or the “Group”), a leading French player on the global surgical technology market for lower-limb orthopedics, announces its sales for the first quarter of its 2019-20 financial year.

Olivier Jallabert, Chairman and CEO of Amplitude Surgical, said: “In the first quarter of our 2019-20 financial year, Amplitude Surgical posted growth of 6.0% at constant exchange rates, driven by an excellent international performance, in particular by subsidiaries. Sales generated in the United States were up 86% compared to the same quarter last year. Novastep, meanwhile, is continuing to ramp-up and now accounts for approximately 10% of total Group revenue, with over 40% growth over the period.”

Q1 2019-20 sales	30/09/2019	30/09/2018	Change at current exchange rates	Change at constant exchange rates
In thousands of euros - IFRS
France	12,091	11,642	+3.9%	+3.9%
International	8,745	7,895	+10.8%	+9.2%
o/w subsidiaries	6,815	5,877	+15.9%	+13.9%
o/w distributors	1,930	2,017	-4.3%	-4.3%
Total	20,837	19,537	6.7%	6.0%

In the first quarter of its 2019-20 financial year (July-September), Amplitude Surgical reported sales of €20.8 million, up 6.7% and 6.0% at constant exchange rates.

• On the French market, Amplitude Surgical recorded a 3.9% increase in activity over the quarter to €12.1 million, i.e. 58% of total sales;
• The Group’s international activity generated sales of €8.7 million, up 10.8% and 9.2% at constant exchange rates, driven by the performance of its subsidiaries (+13.9% at constant exchange rates), notably in South Africa and Brazil, offsetting a temporary downturn in distributors’ activity;
• Amplitude Surgical’s direct business (French market and international subsidiaries), which accounted for almost 91% of total Group sales, recorded growth of 7.2% at constant exchange rates;
• Novastep, which markets innovative solutions for foot and ankle surgery, recorded buoyant growth of 39.7% at constant exchange rates, with quarterly sales of €2.0 million, primarily driven by the United States (+83.9% at constant exchange rates). The proportion of sales generated abroad has increased to over 65%, and Novastep now accounts for 9.4% of the Group’s total sales.

Key first-quarter event